Discover and read the best of Twitter Threads about #cholangiocarcinoma
Most recents (10)
@TumorBoardTues @JohnEbbenMDPhD #TumorBoardTuesday
📣Welcome as we summarize some of the incredible data from #ASCO23
👉There was SO much to take in, that even focusing on GI Cancers was a challenge
🙏As always, these were the🧑🏫that caught OUR interest, but this is not a judgement on those we do not highlight‼️
📣Welcome as we summarize some of the incredible data from #ASCO23
👉There was SO much to take in, that even focusing on GI Cancers was a challenge
🙏As always, these were the🧑🏫that caught OUR interest, but this is not a judgement on those we do not highlight‼️
@TumorBoardTues @JohnEbbenMDPhD 1/21
#TumorBoardTuesday
🤔Speaking for myself, @knutjla ‘s data has shaken my practice the most (including twice last week)
👉He presented the NORPACT-1 trial of peri-operative FOLFIRINOX vs. upfront🔪for resectable #PancreaticCancer
#TumorBoardTuesday
🤔Speaking for myself, @knutjla ‘s data has shaken my practice the most (including twice last week)
👉He presented the NORPACT-1 trial of peri-operative FOLFIRINOX vs. upfront🔪for resectable #PancreaticCancer
@TumorBoardTues @JohnEbbenMDPhD @knutjla @MDAkhilChawla @FlavioRochaMD @NbmerchantMD @MadameSurgeon @NirajGusani @TsengJennifer 2/21
#TumorBoardTuesday
✅@knutjla🗣️a well designed, well run trial
✅The authors even hypothesized a 20%⬆️in mOS
➡️However, pre-operative chemotherapy led to a significant⬇️in 18 month mOS😲
👉Despite a much better R0 resection rate
🤔What are your thoughts💭❓
#TumorBoardTuesday
✅@knutjla🗣️a well designed, well run trial
✅The authors even hypothesized a 20%⬆️in mOS
➡️However, pre-operative chemotherapy led to a significant⬇️in 18 month mOS😲
👉Despite a much better R0 resection rate
🤔What are your thoughts💭❓
😀I am so excited to be at my 1⃣st IN PERSON ASCO GI in 3y
✅To prepare, I have gone through the abstract titles, and here are my Top GI ASCO 2023 abstracts
📣Disclaimer: There is no bias or exclusion intended.
These are just the ones I personally want to see👀
✅To prepare, I have gone through the abstract titles, and here are my Top GI ASCO 2023 abstracts
📣Disclaimer: There is no bias or exclusion intended.
These are just the ones I personally want to see👀
#GI23
➡️Starting with #Cholangiocarcinoma because it is a big year - especially because of:
✅SWOG 1815: A phase III trial of gem-cis-nab-pac vs. gem-cis as 1⃣st line💊for advanced BTC
👁️Rachna Shroff, Abs LBA490
@rachnatshroff
➡️Starting with #Cholangiocarcinoma because it is a big year - especially because of:
✅SWOG 1815: A phase III trial of gem-cis-nab-pac vs. gem-cis as 1⃣st line💊for advanced BTC
👁️Rachna Shroff, Abs LBA490
@rachnatshroff
#GI23
➡️Two impt ImmunoTx trials:
✅IMbrave151: Phase 2 trial of gem-cis-atezo + /- bev as 1⃣st line💊for advanced BTC
👁️A El-Khoueiry, Abs 491
✅Also a TOPAZ-1 report on the long-term survivors Txed with gem-cis-durva 1⃣st line for advanced BTC
👁️M Bouattour, Abs 531, Pos C1
➡️Two impt ImmunoTx trials:
✅IMbrave151: Phase 2 trial of gem-cis-atezo + /- bev as 1⃣st line💊for advanced BTC
👁️A El-Khoueiry, Abs 491
✅Also a TOPAZ-1 report on the long-term survivors Txed with gem-cis-durva 1⃣st line for advanced BTC
👁️M Bouattour, Abs 531, Pos C1
I've been diagnosed with cholangiocarcinoma one month ago. Today I decided to go public to help raise awareness on this rare but raising disease.
The @CCA_Alliance aims to establish a global voice for #cholangiocarcinoma – support them by signing the GCA pledge today & share it #BileDuctCancer globalccaalliance.com/en/get-involve…
How this has started for me. I had some stomach ache back in July, doctor thought was a stomach bug -damn chicken wings-! And then again in early September. Symptoms were slightly different from my standard gastritis but didn't pay attention at the time.
🚨 #CME Thursday 🚨
This week at #TumorBoardTuesday @W_Park_MD discussed FGFR inhibitors in #BiliaryTractCancer #CCA...and how to find FGFR fusions!
Check out the questions below, and tap the link to claim your free #CME...and stay tuned for a special edition of case wrap up!
This week at #TumorBoardTuesday @W_Park_MD discussed FGFR inhibitors in #BiliaryTractCancer #CCA...and how to find FGFR fusions!
Check out the questions below, and tap the link to claim your free #CME...and stay tuned for a special edition of case wrap up!
#PostTest Q 1️⃣ #CME #TumorBoardTuesday
👉🏽 ALL CME🔗 integrityce.com/tbt
🤔 What is a molecular biomarker for an FDA approved🎯💊in #Cholangiocarcinoma❓
#OncTwitter #GeneTesting #CCA
👉🏽 ALL CME🔗 integrityce.com/tbt
🤔 What is a molecular biomarker for an FDA approved🎯💊in #Cholangiocarcinoma❓
#OncTwitter #GeneTesting #CCA
#PostTest Q 2️⃣ #CME #TumorBoardTuesday
👉🏽 ALL CME🔗 integrityce.com/tbt
🤔 To detect 🧬 gene rearrangement what is the preferred method❓
#OncTwitter #GeneTesting #CCA
👉🏽 ALL CME🔗 integrityce.com/tbt
🤔 To detect 🧬 gene rearrangement what is the preferred method❓
#OncTwitter #GeneTesting #CCA
1/12 #TumorBoardTuesday #CCA
56y 🚭M w/ abd pain, 🚫🍻, 🚫Hx hepatitis
FHx - uncle (80) CRC, aunt (40) breast Ca
📷CT: 9cm liver mass with portal vein clot
🔦EGD/Colonoscopy unrevealing
🔬Bx: poorly diff adenoCa. pMMR, PD-L1 CPS 0%
Unresectable IHCC, PS 0, how would U Tx?
56y 🚭M w/ abd pain, 🚫🍻, 🚫Hx hepatitis
FHx - uncle (80) CRC, aunt (40) breast Ca
📷CT: 9cm liver mass with portal vein clot
🔦EGD/Colonoscopy unrevealing
🔬Bx: poorly diff adenoCa. pMMR, PD-L1 CPS 0%
Unresectable IHCC, PS 0, how would U Tx?
2/12 #TumorBoardTuesday
💊Tx with G/C for 4mo➡️SDz
✂️Still unresectable
But…G2✋🏽🦶🏽neuropathy
🩺Outside tumor board discussion suggested switching Tx.
Tumor NGS
👉ARID1A S745fs
🤔What would you choose for next Tx?
💊Tx with G/C for 4mo➡️SDz
✂️Still unresectable
But…G2✋🏽🦶🏽neuropathy
🩺Outside tumor board discussion suggested switching Tx.
Tumor NGS
👉ARID1A S745fs
🤔What would you choose for next Tx?
3/12 #TumorBoardTuesday Mini-Tweetorial 1 👨🏫
#BiliaryTractCancer @curecc @CCA_Alliance
➡️ Other 1L Tx's
✅Ph2 high ORR for GCN @rachnatshroff
pubmed.ncbi.nlm.nih.gov/30998813/
✅Ph3 SWOG 1815⌛️data
clinicaltrials.gov/ct2/show/NCT03…
✅TOPAZ-1: G/C+durva⬆️mOS, mPFS, RRvs. G/C
meetings.asco.org/abstracts-pres…
#BiliaryTractCancer @curecc @CCA_Alliance
➡️ Other 1L Tx's
✅Ph2 high ORR for GCN @rachnatshroff
pubmed.ncbi.nlm.nih.gov/30998813/
✅Ph3 SWOG 1815⌛️data
clinicaltrials.gov/ct2/show/NCT03…
✅TOPAZ-1: G/C+durva⬆️mOS, mPFS, RRvs. G/C
meetings.asco.org/abstracts-pres…
Alguna vez te has preguntado el origen de la palabra cáncer? Sirva este colangiocarcinoma para resolver la pregunta. Spolier alert si vas directo al tweet 5 de este hilo.
#livertwitter #GItwitter #medEd #cancer #cholangiocarcinoma #tweetorial #hilo
#livertwitter #GItwitter #medEd #cancer #cholangiocarcinoma #tweetorial #hilo
Cáncer es una palabra que proviene del griego "karkinos", que significa "cangrejo". Esta, a su vez, proviene de "karkah", cangrejo en sánscrito y de su raíz "kar" que significa duro.
Los primeros en denominar a los tumores y otras lesiones ulcerosas como "karkinos" fueron los griegos. Del griego también deriva "carcinoma" ya que el sufijo "oma" hace referencia al tumor, y significa tumor duro o maligno.
@curecc #ccfac2021 @noza512 @HopkinsMedicine presents on excitement about potential for peptide-based #vaccines as #immunotherapy for #cholangiocarcinoma ! Afterall, tumor recognition is king! And neoantigens critical...
@curecc #ccfac2021 @noza512 Combo approach of #neoantigen vaccine + #immunotherapy can be highly effective! But #cholangiocarcinoma has lower #neoantigen burden c/w other tumor, higher T cell exhaustion
@curecc #ccfac2021 @noza512 Trial soon to open...hope for opening for #cholangiocarcinoma in near future? Stay tuned!
#GI21 time for another #Tweetorial🧵 on
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
🧵2️⃣ #GI21
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
🧵3️⃣ #GI21
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
In this thread, I will compile my medical illustrations in oncology and #RadOnc.
Many are from textbook w @DanTrifMD
amazon.com/Absolute-Clini…
based on @ARRO_org study guide for board exams.
A picture is worth 1000 words.
Here is oncology in a few pics.
Many are from textbook w @DanTrifMD
amazon.com/Absolute-Clini…
based on @ARRO_org study guide for board exams.
A picture is worth 1000 words.
Here is oncology in a few pics.
@DanTrifMD @ARRO_org @SpringerNature Starting with pediatrics:
Rhabdomyosarcoma treatment paradigm for cancers of head/neck depends on parameningeal vs non-parameningeal location. PM is an unfavorable site, affects stage. #sarcoma #HNCSM
Rhabdomyosarcoma treatment paradigm for cancers of head/neck depends on parameningeal vs non-parameningeal location. PM is an unfavorable site, affects stage. #sarcoma #HNCSM
@DanTrifMD @ARRO_org @SpringerNature CNS/brain anatomy from sagittal view.
#BTSM
Chapter from @cgr0105, Sameer Nath, from University of Colorado
#BTSM
Chapter from @cgr0105, Sameer Nath, from University of Colorado
